Eycacy of Extracorporeal Shock Wave Treatment in Calcaneal Enthesophytosis
Total Page:16
File Type:pdf, Size:1020Kb
1064 Ann Rheum Dis 2001;60:1064–1067 Ann Rheum Dis: first published as 10.1136/ard.60.11.1064 on 1 November 2001. Downloaded from EYcacy of extracorporeal shock wave treatment in calcaneal enthesophytosis R Cosentino, P Falsetti, S Manca, R De Stefano, E Frati, B Frediani, F Baldi, E Selvi, R Marcolongo Abstract Our study aimed at evaluating the eVects of Objective—To evaluate the eYcacy of ESWT on pain levels and morphological varia- extracorporeal shock wave treatment tions in enthesophytosis and in enthesis. (ESWT) in calcaneal enthesophytosis. Methods—60 patients (43 women, 17 men) Patients and methods were examined who had talalgia associ- Sixty patients (43 women, 17 men) aged 45–68 ated with heel spur. A single blind ran- (mean 55.6), with talalgia associated with heel domised study was performed in which 30 spur, were examined. patients underwent a regular treatment Inclusion criteria were pain over the radio- (group 1) and 30 a simulated one (shocks logically examined heel spur and unsuccessful of 0 mJ/mm2 energy were applied) (group conservative treatment (insole supports, injec- 2). Variations in symptoms were evaluated tions of local anaesthetics and corticosteroids, by visual analogue scale (VAS). Variations treatment with analgesics and non-steroidal in the dimension of enthesophytosis were anti-inflammatory drugs) during the six evaluated by x ray examination. Varia- months before referral to our hospital. All tions in the grade of enthesitis were evalu- patients had used analgesic and non-steroidal ated by sonography. anti-inflammatory drugs, 25 patients from Results—A significant decrease of VAS group 1 (treatment group) and 28 patients was seen in group 1. Examination by x ray from group 2 (control group) used insole sup- showed morphological modifications (re- ports, 15 patients from group 1 and 19 patients duction of the larger diameter >1 mm) of from group 2 had received injections of local the enthesophytosis in nine (30%) pa- anaesthetics and corticosteroids. tients. Sonography did not show signifi- Exclusion criteria were arthritis (rheumatoid cant changes in the grade of enthesitis just arthritis, spondarthritis, crystal induced ar- after the end of the treatment, but a thropathies), neurological abnormalities, nerve significant reduction was seen after one entrapment syndrome, pregnancy, age under month. In the control group no significant 18 years, infectious or tumorous diseases, skin decrease of VAS was seen. No modification ulcerations, and bursitis. was observed by x ray examination or All patients were informed of, and consented sonography. to, the treatment methods. No other treatment http://ard.bmj.com/ Conclusion—ESWT is safe and improves or drug was used during the four weeks before the symptoms of most patients with a the trials began or during the study period. painful heel, it can also structurally During the periods of treatment and follow up modify enthesophytosis, and reduce in- only the use of insole supports was permitted. flammatory oedema. Consecutive patients were randomly as- (Ann Rheum Dis 2001;60:1064–1067) signed to one of two groups in a single blind study. Group 1, comprising 30 patients (18 women, 12 men) with a mean duration of on September 27, 2021 by guest. Protected copyright. Painful heel is a common syndrome character- symptoms of 8.6 months (range 6–12), re- ised by severe pain in the inferior or posterior ceived ESWT. Group 2 was the placebo group, aspect of the heel, which is aggravated by comprising 30 patients (25 women, five men) weight bearing, becoming progressively worse with a mean duration of symptoms of 8.2 Institute of and often incapacitating, with evidence of a months (range 6–12). Rheumatology, spur in about 50% of cases.1 Until now the An ESWT system was used (“Orthima”, University of Siena, Italy cause of the condition has been obscure, but Direx Medical System Ltd) that is character- R Cosentino numerous factors have been claimed to pro- ised by an electrohydraulic shock wave source P Falsetti duce painful heel with a bony spur: functional assembled on a mobile arm with a full range of S Manca overuse, degenerative diseases, inflammatory movement. It is also equipped with a sono- R De Stefano diseases, and metabolic diseases.2 graphic system with a linear array 7.5 MHz E Frati The conservative methods of treatment usu- probe. Groups 1 and 2 both received six treat- B Frediani F Baldi ally adopted have included insole supports, ments (one every 7–10 days), each treatment E Selvi injections of local anaesthesia and corticoster- consisting of 1200 shocks with a frequency of R Marcolongo oids, and treatment with antiphlogistic 120 shocks/min; the energy density used varied drugs.34 from 0.03 to 0.4 mJ/mm2 in group 1 and was 0 Correspondence to: Extracorporeal shock wave treatment mJ/mm2 in group 2. The shocks were aimed at Dr R Cosentino, Institute of Rheumatology, Policlinico Le (ESWT) is based on the use of shock waves— the enthesophytosis which was identified dur- Scotte, Viale bracci, 53100 that is, microsecond pressure impulses, which, ing sonographic examination. Siena, Italy depending on the energy used, can reduce Variations in the dimension of the larger [email protected] painful symptoms and fragmentation of calcific diameter of enthesophytosis were evaluated by Accepted 12 April 2001 deposits.1 5–7 x ray examination at baseline and after one www.annrheumdis.com Calcaneal enthesophytosis 1065 Ann Rheum Dis: first published as 10.1136/ard.60.11.1064 on 1 November 2001. Downloaded from VAS after walking VAS after normal VAS when at rest on awakening daily activity 10 10 10 * 8 8 † * 8 † * * † † 6 6 6 * * * † * † † † VAS * † 4 4 4 2 2 2 0 0 0 Before After 1 Month 3 Months Before After 1 Month 3 Months Before After 1 Month 3 Months ESWT ESWT ESWT ESWT ESWT ESWT Group 1 Group 2 Figure 1 Mean visual analogue scale (VAS) score before extracorporeal shock wave treatment (ESWT), after ESWT,and one and three months later, at rest, after walking on awakening, and after normal daily activity. *p<0.0001, group1vgroup 2; †p<0.0001 group 1, baseline v after ESWT,after one month, and after three months. month from the end of the treatment (one compare variations of means of VAS, changes of radiologist carried out all the radiography and sonographic evaluations (grading of enthesitis), was not aware of the type of treatment being and variations of the larger diameter of spurs in given to the patients). The modifications treated patients compared with control pa- observed were classified as grade 1 (reduction tients. The non-parametric Wilcoxon test for in enthesophytosis <1 mm), grade 2 (reduction in enthesophytosis >1 mm). Variations in the grade of enthesitis were evaluated by sonography on the heel before starting the treatment, just after the treatment, and one month later (one ultrasonographer carried out all the sonography and was not aware of the type of treatment being given to the patients). Ultrasound examinations were carried out with a Toshiba Tosbee Sal 240 with http://ard.bmj.com/ a linear 7.5 MHz probe and a kitecho gel pad spacer where necessary. The following signs of enthesitis were considered: enthesophytosis, heterogeneous hypoechogenicity and swelling of enthesis, peritendinous oedema. The modi- fications observed were classified as grade 1: thickening of enthesis (<2 mm thicker than the contralateral asymptomatic side), heterogene- on September 27, 2021 by guest. Protected copyright. ous hypoechogenicity of enthesis, and entheso- phytosis; grade 2: thickening of enthesis (>2 mm thicker than the contralateral asympto- matic side), heterogeneous hypoechogenicity of enthesis, and enthesophytosis; grade 3: grade 2 with peritendinous oedema.89 Pain levels were evaluated by a visual analogue scale (VAS), ranging from0=nopain to 10 = maximum pain, at rest, after walking on awakening, and after normal daily activity. Such assessment was made before, at the end of the treatment, and one and three months after the end of the treatment. The modifica- tions observed were classified as excellent improvement (a VAS reduction of over 50%), good improvement (a VAS reduction of between 30% and 50%), slight improvement (a Figure 2 (A) Enthesitis of the plantar fascia (sonographic VAS reduction of between 15% and 30%). grade 3) before extracorporeal shock wave treatment (ESWT). (B) The same patient as in fig 2A, examined STATISTICS one month after the end of ESWT.An improvement of enthesitis (disappearance of the paratendinitis, reduction of A non-parametric Mann-Whitney U test for thickness of the plantar fascia origin, modification of the two independent samples was applied to subcalcaneal spur) can be seen. www.annrheumdis.com 1066 Cosentino, Falsetti, Manca, et al Ann Rheum Dis: first published as 10.1136/ard.60.11.1064 on 1 November 2001. Downloaded from Examination by x ray showed reduction in enthesophytosis >1 mm of 9/30 (30%) patients and reduction in enthesophytosis <1 mm or no change in 21/30 (70%) patients. Radiological reduction of enthesophytosis 1 month after the end of treatment was significant in group 1 (p<0.001), but not significant (p=0.068) in comparison with the control group (fig 3). No side eVects were seen. A temporary, slight redness of the skin and a transient increase in pain levels were within the norm. Discussion High energy extracorporeal shock waves have been used in urology for the disintegration of stone concretion for almost 15 years.10 Valcha- nou reported the successful application of high energy shock waves in the treatment of